Trial
NCT01441193
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Barbara Ensoli, MD
Collaborators
Novartis Vaccines
Condition
HIV Infection
Intervention
HIV-1 Tat/delta-V2 Env combined vaccine
Why stopped
Enrollments were suspended due to delta-V2 Env unavailability, following the EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-04